Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Nephrology

Long-Term Management: Monitoring, Relapse Risk, and Discontinuation

At a Glance

Many aHUS patients can now safely pause C5 inhibitor therapy after achieving complete remission for 3 to 6 months. Relapse risk heavily depends on genetics, and a successful pause requires strict home monitoring for symptoms, frequent lab tests, and a rapid re-treatment plan.

For many years, a diagnosis of atypical Hemolytic Uremic Syndrome (aHUS) meant a lifetime of regular infusions. However, as our understanding of the disease has grown, the medical community has shifted toward a more personalized approach [1][2]. While long-term therapy remains the “safest” way to prevent a flare, it is now possible for some patients to safely discontinue treatment under strict medical supervision [3][4].

The Shift Toward Personalized Care

Current research, including the international SETOPAH study, has shown that stopping C5 inhibitor therapy (like eculizumab or ravulizumab) is a feasible strategy for many, provided there is a clear plan for rapid re-treatment if a relapse occurs [1][2].

  • The Eligibility Window: Doctors usually consider stopping therapy only after a patient has been in complete hematologic remission (stable blood counts and kidney function) for at least 3 to 6 months [5][6].
  • Safety of Re-treatment: Evidence suggests that if a relapse is caught early and the medication is restarted immediately, most patients can achieve remission again without suffering permanent kidney damage [1][7].

Understanding Your Relapse Risk

Your specific genetic profile is the most important factor in determining how likely you are to have another flare [8][1].

  • High-Risk Group (~35%+ risk): Patients with known genetic mutations, particularly in the CFH or CD46 genes, have the highest risk of relapse after stopping therapy [1][2].
  • Moderate-Risk Group (~15% risk): Patients who have “negative” genetic tests (no identified mutation) tend to have a lower risk of recurrence, though it is not zero [1].
  • The Autoimmune Exception (Anti-CFH Antibodies): Patients with the autoimmune form of the disease face a unique situation. While relapses are rare if antibody levels remain low, the risk is significant (20-30% or more) if immunosuppression is stopped or if the antibody titers spike during a subsequent infection [1][9]. For these patients, ongoing monitoring of the antibody titers is essential to predict and prevent relapse.

The “Home Watch”: Monitoring for Relapse

If you and your doctor decide to pause treatment, life enters a phase of “active surveillance.” Monitoring is most intense in the first year after stopping [3][10].

  1. Lab Tests: You will need frequent blood tests to check your platelet count, Creatinine (kidney function), and LDH [7][11]. LDH (Lactate Dehydrogenase) is an enzyme released when cells are destroyed. In aHUS, high LDH means your red blood cells are being shredded. Doctors want this number to go down and stay in the normal range.
  2. Urine Monitoring: Many patients are taught to use urine dipsticks at home. A sensitive early sign of a relapse is hemoglobinuria (the presence of blood or hemoglobin in the urine), which can happen before you feel sick [12][7]. It is especially important to test your urine during or immediately after a potential “trigger,” such as a common cold or a vaccination.
  3. Symptom Awareness: You must be vigilant for “red flag” symptoms, especially during or after triggers [7][13]. These include:
    • Dark, “tea-colored” or “coke-colored” urine.
    • Sudden, extreme fatigue or paleness.
    • Unexplained bruising or small red spots on the skin (petechiae).
    • A sudden spike in blood pressure.

The Emotional Landscape

Living “off-therapy” brings a new type of emotional challenge. While you gain freedom from infusions, you may experience “scanxiety” or hyper-vigilance—feeling a surge of panic at every minor cold or headache [14]. It is important to work with a care team that recognizes this emotional toll [15].

Ultimately, the goal of long-term management is to provide the highest quality of life while protecting your kidneys [16]. Whether you remain on lifelong therapy or choose a monitored pause, the decision should be a shared one, based on your genetics, your health history, and your personal comfort with risk [1][17].

Common questions in this guide

Can I ever stop taking my infusions for aHUS?
Yes, some patients can safely pause C5 inhibitor therapy under strict medical supervision. Doctors typically consider stopping treatment only after a patient has been in complete hematologic remission with stable blood counts and kidney function for at least 3 to 6 months.
What increases the risk of an aHUS relapse if I stop treatment?
Your specific genetic profile is the most important factor. Patients with known genetic mutations, particularly in the CFH or CD46 genes, have the highest risk of relapse. Those without identified genetic mutations have a lower risk.
How will my doctor monitor me for an aHUS relapse?
Monitoring is most intense in the first year after stopping therapy. You will need frequent blood tests to check your platelet count, kidney function, and LDH levels. Your doctor may also teach you to use urine dipsticks at home to check for blood in your urine.
What are the warning signs of an aHUS relapse I should watch for at home?
Red flag symptoms include dark or tea-colored urine, sudden extreme fatigue, unexplained bruising, small red spots on the skin, and sudden spikes in blood pressure. You should be especially watchful for these signs during or after a trigger like a common cold.
What happens if my aHUS relapses after stopping medication?
If a relapse is caught early and your medication is restarted immediately, most patients can achieve remission again without suffering permanent kidney damage. This is why having a rapid re-treatment plan in place with your healthcare team is essential.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my specific genetic mutation (or lack thereof), what is my estimated percentage risk of a relapse if I stop therapy?
  2. 2.What exactly does the monitoring schedule look like for the first 6-12 months after stopping treatment?
  3. 3.If I notice a sign of relapse, such as blood in my urine, who is my immediate point of contact and how quickly can I receive a 'rescue dose' of medication?
  4. 4.What specific laboratory markers (like LDH or Creatinine) will you be watching most closely, and how often will I need blood draws?
  5. 5.Are there certain triggers, such as an upcoming surgery or vaccination, where we should temporarily restart or increase my monitoring?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.

    Fakhouri F, Fila M, Hummel A, et al.

    Blood 2021; (137(18)):2438-2449 doi:10.1182/blood.2020009280.

    PMID: 33270832
  2. 2

    Real-world use of complement inhibitors for haemolytic uraemic syndrome: an analysis of the European Rare Kidney Disease Registry cohort.

    Vujović A, Sellier-Leclerc AL, Mancuso MC, et al.

    EClinicalMedicine 2025; (82()):103159 doi:10.1016/j.eclinm.2025.103159.

    PMID: 40224677
  3. 3

    When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies.

    Olson SR, Lu E, Sulpizio E, et al.

    American journal of nephrology 2018; (48(2)):96-107 doi:10.1159/000492033.

    PMID: 30110670
  4. 4

    A new therapeutic strategy for atypical HUS.

    Moake JL

    Blood 2017; (130(3)):243-244 doi:10.1182/blood-2017-06-783704.

    PMID: 28729338
  5. 5

    Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome.

    Yeter HH, Derici U, Arinsoy T, et al.

    Romanian journal of internal medicine = Revue roumaine de medecine interne 2022; (60(1)):56-65 doi:10.2478/rjim-2021-0034.

    PMID: 34449174
  6. 6

    Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study.

    Bouwmeester RN, Duineveld C, Wijnsma KL, et al.

    Kidney international reports 2023; (8(1)):91-102 doi:10.1016/j.ekir.2022.10.013.

    PMID: 36644349
  7. 7

    COVID-19 vaccination and Atypical hemolytic uremic syndrome.

    Bouwmeester RN, Bormans EMG, Duineveld C, et al.

    Frontiers in immunology 2022; (13()):1056153 doi:10.3389/fimmu.2022.1056153.

    PMID: 36531998
  8. 8

    Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.

    Fakhouri F, Fila M, Provôt F, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2017; (12(1)):50-59 doi:10.2215/CJN.06440616.

    PMID: 27799617
  9. 9

    Membrane-filtration based plasma exchanges for atypical hemolytic uremic syndrome: Audit of efficacy and safety.

    Khandelwal P, Thomas CC, Rathi BS, et al.

    Journal of clinical apheresis 2019; (34(5)):555-562 doi:10.1002/jca.21711.

    PMID: 31173399
  10. 10

    Multidisciplinary consensus on the diagnosis and management of patients with atypical Hemolytic Uremic Syndrome (complement-mediated TMA): Recommendations from Italian scientific societies, patient associations and regulators.

    Stea ED, Pugliano M, Gualtierotti R, et al.

    Pharmacological research 2025; (216()):107714 doi:10.1016/j.phrs.2025.107714.

    PMID: 40204022
  11. 11

    Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab.

    Cammett TJ, Garlo K, Millman EE, et al.

    Molecular diagnosis & therapy 2023; (27(1)):61-74 doi:10.1007/s40291-022-00620-3.

    PMID: 36329366
  12. 12

    Haemoglobinuria for the early identification of aHUS relapse: data from the ItalKId-HUS Network.

    Brambilla M, Ardissino G, Paglialonga F, et al.

    Journal of nephrology 2022; (35(1)):279-284 doi:10.1007/s40620-021-00965-8.

    PMID: 33459950
  13. 13

    [Atypical hemolytic uremic syndrome: differential diagnosis and therapy - A clinical practice guideline for diagnosis and therapy].

    Gäckler A, Brinkkötter PT

    Deutsche medizinische Wochenschrift (1946) 2025; (150(4)):167-172 doi:10.1055/a-2382-6433.

    PMID: 39879972
  14. 14

    Altered Theory of Mind in Parkinson's Disease and Impact on Caregivers: A Pilot Study.

    Giguère-Rancourt A, Plourde M, Racine E, et al.

    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2022; (49(3)):437-440 doi:10.1017/cjn.2021.110.

    PMID: 33988099
  15. 15

    Impact of burnout and spiritual well-being on caregiver burden in parents of children with cancer.

    Akbulut Uğur Aİ, Kızılırmak Tatu M

    Journal of pediatric nursing 2025; (84()):208-216 doi:10.1016/j.pedn.2025.06.016.

    PMID: 40516290
  16. 16

    Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials.

    Dixon BP, Kavanagh D, Aris ADM, et al.

    Kidney medicine 2024; (6(8)):100855 doi:10.1016/j.xkme.2024.100855.

    PMID: 39105067
  17. 17

    Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis.

    Gonzalez Suarez ML, Thongprayoon C, Mao MA, et al.

    Journal of clinical medicine 2019; (8(7)) doi:10.3390/jcm8070919.

    PMID: 31252541

This page provides educational information about aHUS long-term management and therapy discontinuation. Always consult your nephrologist or hematologist before changing your treatment plan.

Get notified when new evidence is published on Atypical hemolytic uremic syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.